Fig. 7: Combination therapy of lorlatinib, Src family kinase inhibitor, and EGFR inhibitor showed significant suppression of cell viability in lorlatinib-acquired resistance cells. | npj Precision Oncology

Fig. 7: Combination therapy of lorlatinib, Src family kinase inhibitor, and EGFR inhibitor showed significant suppression of cell viability in lorlatinib-acquired resistance cells.

From: GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer

Fig. 7

Cell viability of a JFCR-028-5 and b JFCR-278 cells treated with the indicated concentration of lorlatinib with or without a fixed concentration of dasatinib or afatinib for 72 h (n = 3). Each point represents the mean ± SD of three replicates. Western blot analysis showing suppression of phospho-ALK and its downstream signaling in c JFCR-028-5 and d JFCR-278 cells treated with 30 nM lorlatinib in the absence or presence of the indicated concentration of dasatinib or afatinib for 0, 3, and 24 h. GAPDH was used as a loading control.

Back to article page